Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month price objectives for Lantheus' shares. Their LNTH share price targets range from $100.00 to $127.00. On average, they anticipate the company's stock price to reach $110.71 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH shares have increased by 43.2% and is now trading at $72.96.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our LNTH earnings forecast.

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its earnings results on Thursday, November, 2nd. The medical equipment provider reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.10. The medical equipment provider had revenue of $319.95 million for the quarter, compared to analyst estimates of $315.01 million. Lantheus had a trailing twelve-month return on equity of 70.13% and a net margin of 8.63%.

ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX).

Lantheus issued an update on its FY23 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $5.60-$5.70 for the period, compared to the consensus estimate of $5.68. The company issued revenue guidance of $1.245-$1.270 billion, compared to the consensus revenue estimate of $1.26 billion.

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (3.13%), American Century Companies Inc. (1.90%), Westfield Capital Management Co. LP (1.89%), Invesco Ltd. (1.54%), Northern Trust Corp (1.44%) and Reinhart Partners LLC. (1.32%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.